Acrivon Therapeutics closed at $1.74 on Nov 4, up 4.19%, 42.2% below its 52-week closing high. Volume of 127.9K shares was 0.64× its 20-day average (below normal).
Split-adjusted performance: -6.5% over one month, -16.7% over six months, -25.3% over one year.
Short interest was 1.7M shares at the Oct 15 settlement, up 7.5% from the prior report (7.2% of float, 6.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ACRVAcrivon Therapeutics | $1.74 | +4.19% | −16.7% | — | — | — | $74.6M | |
| LFVNLifevantage Corporation Common Stock (Delaware) | $5.97 | +3.65% | −0.5% | −23.1% | 3.0% | 14.8 | $75.2M | Compare |
| FTLFFitLife Brands | $8.18 | +3.68% | −12.1% | +64.6% | 7.3% | 12.3 | $76.8M | Compare |
| COYACoya Therapeutics | $3.08 | −0.96% | −27.4% | +49.0% | −2723.4% | — | $72.3M | Compare |
| MNOVMedicinova | $1.45 | +2.11% | 0.0% | +240.6% | −504.8% | — | $71.4M | Compare |
| PMVPPMV Pharmaceuticals | $1.33 | −3.99% | −8.6% | — | — | — | $70.8M | Compare |
| MAIAMAIA Biotechnology | $1.14 | +5.56% | −15.6% | — | — | — | $70.4M | Compare |
| CRBPCorbus Pharmaceuticals Holdings | $3.57 | −7.75% | −67.3% | — | — | — | $69.0M | Compare |
| TENXTenax Therapeutics | $1.81 | −1.63% | −84.9% | — | — | — | $67.7M | Compare |
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
